triumph 1 trial retatrutide just had its biggest data year yet. In 2026, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Triumph-1 Trial Results for Retatrutide
Description
Clinical trials report up to 12.4% weight loss, and it stands out for its flexible dosing
Brown adipose tissue: Function and physiological significance
The personalized medical weight loss options offered by our providers may include GLP-1 medications such as Semaglutide or Liraglutide, depending on individual needs and availability
They include : Nausea Constipation Vomiting Diarrhea Burping (eructation) Indigestion (dyspepsia) Stomach pain Headache Fatigue Reflux Flatulence (gas) Hair loss As with other GLP-1s, more serious side effects are possible, such as an inflamed pancreas or low blood sugar (hypoglycemia)
Overweight, obesity, youth, and health-risk behaviors
